Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP). (MosuOSSHSR)

Andrés José Maria Ferreri

Status: Enrolling

Conditions: Relapsed/Refractory Follicular Lymphoma

Treatments: Drug: Mosunetuzumab

Study type: Observational

Funder types: Other

Identifiers

NCT07278921

MosuOSSHSR

Details and patient eligibility

About

Retrospective, multicenter observational study to evaluate the response to treatment with Mosunetuzumab in relapsed/refractory Follicular Lymphoma (FL) after at least three lines of therapy, within the Compassionate Use Program (CUP).

Enrollment: 25 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients (>18 years) with follicular non-Hodgkin's lymphoma, undergoing at least two lines of therapy, treated with mosunetuzumab under a compassionate use program.
• Patients who have signed informed consent for treatment.

Exclusion criteria

• Age <18 years
• Patients with other types of cancer/lymphoma
• Patients not eligible for the Mosunetuzumab compassionate use program